Abstract: An isolated DNA sequence capable of directing gene expression comprising a hRAR-.alpha. promoter or a hRAR-.alpha. promoter element, expression vectors containing the DNA sequence and host cells containing the expression vectors.
Type:
Grant
Filed:
December 10, 1990
Date of Patent:
July 13, 1999
Assignee:
Bristol-Myers Squibb Co.
Inventors:
Pierre Chambon, Nigel J. Brand, Martin Petkovich
Abstract: The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.
Abstract: Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.
Type:
Grant
Filed:
December 19, 1996
Date of Patent:
October 20, 1998
Inventors:
Dalton King, Raymond A. Firestone, Pamela Trail
Abstract: The molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180.sup.erbB4, are described. Antibodies to HER4 are disclosed. A HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin, various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 22, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
Gregory D. Plowman, Jean-Michel Culouscou, Mohammed Shoyab, Clay B. Siegall, Ingegerd Hellstrom, Karl E. Hellstrom
Abstract: The instant invention relates to a novel method for the delivery of antitumor drugs to tumor cells by the administration of a tumor-selective antibody-.beta.-lactamase conjugate that binds to tumor cells, and the additional administration of a cephalosporin prodrug that is converted at the tumor site, in the presence of the antibody-.beta.-lactamase, to an active cytotoxic drug. According to the preferred embodiment of this invention, a cephalosporin mustard has been constructed which when cleaved by .beta.-lactamase yields a cytotoxic nitrogen mustard. The methods, antibody-enzyme conjugate, prodrugs, pharmaceutical compositions, and combinations of this invention provide for enhanced selective killing of tumor cells and are thus useful in the treatment of cancers and other tumors.
Type:
Grant
Filed:
February 9, 1993
Date of Patent:
June 30, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
John Kadow, Takushi Kaneko, Peter D. Senter, Vivekanada M. Vrudhula
Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.
Type:
Grant
Filed:
September 22, 1995
Date of Patent:
June 16, 1998
Assignee:
Oncogen
Inventors:
Ingegerd Hellstrom, Karl Erik Hellstrom, Victor K. Lee
Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.
Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## (I) in whichD is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ C1.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
January 13, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
Abstract: The present invention relates to new antifungal compounds having the formula ##STR1## wherein R.sup.1 is hydrogen, methyl, or hydroxymethyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen and C.sub.1-5 alkyl; and R.sup.4 is selected from the group consisting of .beta.-L-xylosyl, .beta.-D-ribosyl, .alpha.-L-arabinosyl, .beta.-D-chinovosyl, .beta.-D-fucosyl, and .beta.-D-glucosyl; with the proviso that when R.sup.1 is methyl or hydroxymethyl, and one of R.sup.2 or R.sup.3 is methyl, R.sup.4 is not .beta.-D-glucosyl; or a pharmaceutically acceptable salt thereof.
Abstract: The present invention is directed to a method for inhibiting Helicobacter by administering C.sub.8 -C.sub.16 monoglycerides of fatty acids or lauric acid. The monoglycerides and/or lauric acid are conveniently administered via a nutritional composition.
Abstract: Expression vectors for human topoisomerase I and a method for detecting poisons of human topoisomerase I. The vector preferably contains a promoter, DNA coding for human topoisomerase I, DNA coding for a selectable marker, an origin of replication, and lac I.sup.q DNA which encodes a repressor for the promoter.
Abstract: The present invention relates to intermediates, pradimic acids and pradimic acid amides of the formula (II) ##STR1## wherein R is OH or NH.sub.2 ; R.sup.1 is hydrogen or a group of the formula ##STR2## with the proviso that when R is OH, R.sup.1 is not hydrogen; Y is OH or NR.sup.2 R.sup.3 ; R.sup.2 is hydrogen or methyl; R.sup.3 is hydrogen, C.sub.1-5 alkyl, or an amino protecting group; R.sup.4 is hydrogen, hydroxy protecting group, or .beta.-D-xylosyl.The invention relates also to novel processes for the preparation of pradimic acids and pradimic acid amides, as well as novel pradimicin derivatives prepared therefrom.
Abstract: Disclosed is a milk protein partial hydrolysate prepared by enzymatic hydrolysis and infant formula prepared therefrom. The hydrolysate has reduced antigenicity and is prepared from a mixture of whey protein and casein wherein the degree of hydrolysis is between 4 and 10%.
Type:
Grant
Filed:
November 21, 1994
Date of Patent:
December 31, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Sarah B. Martinez, H. Lee Leary, Jr., Debra J. Nichols
Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of a squalene synthetase, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of a squalene synthetase, and methods for producing these polypeptide molecules.
Abstract: A new chimeric plasminogen activator with high fibrin affinity was designed to bind to a fibrin clot and initiate clot destruction in the presence of thrombin, but not plasmin. The chimeric molecule has an antibody variable region having a fibrin-specific antigen binding site and a single chain urokinase region having a thrombin activation site but not a plasmin activation site. The preferred embodiment, 59D8-ScuPA-T, has an N-terminal fragment of an anti-fibrin antibody (59DB) and a C-terminal thrombin-activatable low molecular weight single-chain urokinase plasminogen activator (scuPA-T). The scuPA-T portion was obtained by deletion of two amino acids (Phe157 and Lys 158) that make up the plasmin activation site from low molecular weight single chain urokinase-type plasminogen activator (scuPA).
Type:
Grant
Filed:
April 19, 1993
Date of Patent:
November 5, 1996
Assignee:
Bristol-Myers Squibb Company
Inventors:
Wen-Pin Yang, Gary R. Matsueda, Shyh-Yu Shaw
Abstract: Method for lowering viscosity in nutritional compositions containing soy fiber by addition of gum acacia. The composition is preferably nutritionally complete and optionally contains protein, non-fiber carbohydrate, and other nutrients.
Abstract: Disclosed is the novel compound BU-4664L and derivatives thereof. The compound is produced by fermentation of Micromonospora sp. M990-6. The compound possesses anti-inflammatory and/or anti-tumor cell activities.